Skip to main content
Clinical Trials/DRKS00029537
DRKS00029537
Not yet recruiting
未知

Examination of the cytokine brain-derived neurotrophic factor after SARS-CoV-2 infection

Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg0 sites72 target enrollmentJuly 21, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Post-Covid-Syndrome ICD-10:U09.9
Sponsor
Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg
Enrollment
72
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 21, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Klinik für Allgemeine Psychiatrie, Universitätsklinikum Heidelberg

Eligibility Criteria

Inclusion Criteria

  • Ability to provide informed consent, age \= 18 years, history of SARS\-CoV\-2 infection.
  • Group 1: new or worsened psychiatric symptoms concerning affectivity, energy levels and tiredness, cognition or anxiety and stress related problems that have started after SARS\-CoV\-2 infection and are persistent on the day of examination, but no shorter than 12 weeks (so called post\-covid\-syndrom).
  • Group 2: no residual symptoms of after SARS\-CoV\-2 infection.

Exclusion Criteria

  • 1\. unable to provide informed consent
  • 2\. acute, severe somatic or psychiatric illnesses, such as:
  • psychiatric:
  • \- acute psychosis
  • \- acute suicidal ideation
  • \- acute mania
  • \- acute intoxication
  • \- severe anxiety/OCD/depressive symptoms impeding the examination
  • \-acute neurologic or somatic illnesses that require medical attention such as acute infections, pain or injuries
  • \-persistent or chronic conditions that may impede the examination (particularly sensory or motor deficits)

Outcomes

Primary Outcomes

Not specified

Similar Trials